Access

Velphoro is accessible and affordable for most patients1,2

MEDICARE PART D

For patients who qualify for full Low Income Subsidy (LIS) Extra Help and/or are on Medicaid

  • Most patients pay ≤$10.35 per monthly prescription*2
    • A majority of these patients will have a $0 copay with no deductible1
    • Direct eligible patients to enroll online at SSA.gov, where they can fill out and submit an application

 

For patients on Medicare Part D Standard

  • With a household income between 1.5 and 4.5 times the federal poverty limit, up to $135,000 for a family of four3 
  • Patients with out-of-pocket costs of >$50 will be automatically referred to the Patient Assistance Program (PAP)† 
    • Fill out the PAP application provided by your Velphoro Access Solutions Case Manager and obtain the appropriate signatures

 

For patients new to dialysis who have a Medicare application pending within 90 days

  • Velphoro Bridge Program provides up to 90 days of Velphoro at no cost
    • Call Velphoro Access Solutions at 877-774-6756

COMMERCIAL INSURANCE

Patients with commercial insurance and copay, coinsurance, or a deductible

  • Velphoro Copay Savings Program: Most patients will pay $0 for Velphoro1
    • Copay savings are automatic; no card required‡

 

Assistance for eligible patients

  • With a household income between 1.5 and 4.5 times the federal poverty limit, up to $135,000 for a family of four3
  • Patients with out-of-pocket costs of >$50 will be automatically referred to the Patient Assistance Program (PAP)†
    • Fill out PAP application provided by your Velphoro Access Solutions Case Manager and obtain the appropriate signatures

Starting new patients on Velphoro is easy with
Velphoro Access Solutions

  1. Visit the HCP portal to sign up and log in at VelphoroPathways.com. Initiate benefits investigations for patients, track their application status, monitor their benefits, and access all patient programs provided by Fresenius Renal Pharmaceuticals.

    Fresenius Kidney Care: Please continue to access benefits investigation via ePOC.

  2. Download a benefits investigation application and fax back to Velphoro Access Solutions at 1-866-496-8638.

Contact Velphoro Access Solutions

Velphoro Access Solutions representatives are available to answer questions 
from 8 am to 8 pm ET at 1-877-774-6756

 

*In 2023, patients who qualify for full Extra Help pay no more than $10.35 per prescription. Patients who qualify for partial Extra Help pay no more than 15% of the cost of the drug until they reach the out-of-pocket limit.2

†Patients with commercial insurance may be eligible for PAP program if out-of-pocket costs are deemed too high with savings program. Eligibility requirements apply.

‡Reimbursement options are available for patients using mail-order fulfillment. Through our partnership with RelayHealth, a card is not required for automatic application of savings at all participating in-network pharmacies. A small percentage of independent or out-of-network pharmacies may still require a downloadable copay card, available at VelphoroCoupon.com. Savings realized after application of automatic $0 copay.

References: 1. Data on file. Fresenius Medical Care North America, Waltham, MA. 2. Medicare.gov. Help with drug costs. https://www.medicare.gov/basics/costs/help/drug-costs. Accessed November 16, 2022. 3. Office of the Assistant Secretary for Planning and Evaluation; US Department of Health and Human Services. Poverty guidelines. https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines. Accessed March 9, 2023.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451

Fresenius Medical Care Renal Pharmaceuticals
PRIVACY NOTICE
TERMS OF USE
NOTICE OF PRIVACY PRACTICES
PRESCRIBING INFORMATION
CONTACT US
SITEMAP

© 2023 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care and the triangle logo are trademarks of Fresenius Medical Care Holdings, Inc. Velphoro is a trademark of Vifor Fresenius Medical Care Renal Pharma Ltd. All other trademarks are the property of their respective owners.

Do Not Sell or Share My Personal Data • Limit the Use of My Sensitive Personal Information